HomeCorporateFDA Issues New Guidance for Veterinary Monoclonal Antibody Safety Evaluation

FDA Issues New Guidance for Veterinary Monoclonal Antibody Safety Evaluation

The U.S. FDA Center for Veterinary Medicine (FDA-CVM) has issued new guidance addressing target-animal safety evaluation for veterinary monoclonal antibody products.

The guidance forms part of the VICH framework and provides developers with regulatory expectations for assessing the safety of monoclonal antibody products in their intended animal populations.

Monoclonal antibodies are becoming an increasingly important class of targeted veterinary therapeutics, particularly in companion-animal medicine.

fda-veterinary-monoclonal-antibody-guidance
fda-veterinary-monoclonal-antibody-guidance

Industry significance

The guidance represents an important regulatory development for the veterinary-biologics pipeline. Greater clarity around safety evaluation can help companies planning innovative antibody-based therapies structure development programmes and regulatory submissions more effectively.

The development also reflects the increasing sophistication of veterinary medicine, with targeted biologics complementing conventional pharmaceuticals.

Animal Health India Editorial Team
Animal Health India Editorial Teamhttps://animalhealthindia.com
Animal Health India (AHI) is an independent news and intelligence platform covering the global animal health, veterinary, livestock, poultry, companion animal and pet food sectors. Our editorial team comprises veterinary journalists, animal health professionals, regulatory affairs specialists and industry analysts with over 30 years of combined experience covering India, Asia, Europe and North America. AHI publishes news, regulatory updates, market intelligence and company news drawn from primary sources including DAHD, EMA, USDA, AVMA and leading veterinary publications worldwide.
RELATED ARTICLES